Boehringer Ingelheim To Close Early Research Department In Japan
This article was originally published in PharmAsia News
Executive Summary
Boehringer Ingelheim’s Kobe Pharma Research Institute will continue to operate, but is expected to be stripped of its molecular and cellular biology capabilities.